The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer
Using combination of gemcitabine plus cisplatine as first line treatment patients with locally advanced breast cancer with high TUBB3 expression
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Every 21 days 6 cycles
Every 21 days (First and 8th days) 6 cycles
Every 21 days 4 cycles
Elchin Mansurov
Baku, Azerbaijan
Clinical tumor regression rate
Chemotherapy combination Gemcitabine with Cisplatin
Time frame: 4 months
Increasing PFS and OS
Observation after chemotherapy
Time frame: 5 years and 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Every 21 days 4 cycles
Every 21 days 4 cycles or once a week for 12 weeks